Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed at an advanced stage, where it is very difficult to treat.
To help raise awareness for ovarian cancer, Cartherics hosted a Teal Ribbon Day afternoon tea. Our Teal Tea provided a great opportunity to bring people […]
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.
The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for […]
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when survival outcomes are worse. Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for early next […]
Melbourne, Australia, 1 February 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its […]
Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at Crown Promenade in Melbourne.
The Australia Biologics Festival aims to gather the innovators, pioneers and leaders in the biologics industry, including biologics, biosimilars, vaccines, cell and gene therapy (CGT) and evolving therapeutics, to showcase the […]
BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in 2023. Cartherics’ COO, Dr Ian Nisbet contributed to the article, commenting on the challenges for life sciences companies in the region, particularly smaller and private companies, to raise new capital. He also discussed the impact […]
As published in Drug Target Review
Professor Alan Trounson, AO
Dr Huimin Cao
Dr Aleta Pupovac
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data from clinical trials, but is this really a valid belief at the present stage of development of the immune therapy […]
Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian cancer. CTH-401 is the only NK cell product currently under development that targets the adenocarcinoma specific antigen – TAG-72.
The company is looking to raise up to AU$20 million to support its ongoing development activities and […]
China is Australia’s greatest two-way trading partner in products and services, making up close to one-third of the nation’s international trade, as per the Australian Department of Foreign Affairs and Commerce. Resources and energy make up the largest share of Australia’s exports to China, with iron ore, natural gas and gold leading the way.
There are a number […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
